Open Journal Systems

Clinical Outcome of Patients of Acute Coronary Syndrome at 7 and 30 days Undergoing Percutaneous Coronary Interventions and Treated with Bivalirudin and Heparin

Kumar A, Kachhadiya R, Chakraborty BS

Abstract


Background:Recent data suggest that Bivalirudin provides ischemic protection superior to Heparin,and comparable to Heparin plus glycoprotein IIb/IIIa inhibitors, with significantly fewer bleeding complications. Whetherthis advantage persists in large population has not beenfully defined. Objective: This study systematically evaluates clinical outcomes of treatment with Bivalirudinvs Heparin in patients of acute coronary syndrome undergoing Percutaneous coronary interventions (PCI). Methods: We analyzed prospective, randomized controlled trials via electronic searches that have reported clinical outcomes at 7 and 30 days. The outcomes were major bleeding, net clinical outcomes and Major Adverse Cardiac Events – MACE. Data from individual trials were combined by a meta analysis method of Mantel-Haenszelcalculate a relative risk (RR) and 95% confidence interval (95%CI) across the studies.Theheterogeneity across the trials was assessed through χ2 statistic, I2 andvisual inspection of the forest plots. Results: This meta-analysis involved a total of 30,088 patients (Bivalirudin, n=15,105; Heparin, n=14,983). Compared with Heparin, Bivalirudin was associated with a lower risk of major bleeding (RR 0.38; 95%CI 0.29-0.48 at 7 days and RR 0.67;95%CI 0.60-0.75 at 30 days), net clinical outcomes (RR 0.56; 95%CI 0.47-0.66 at 7 days and RR 0.89; 95%CI 0.83- 0.96 at 30 days) and MACE (RR 0.78; 95%CI 0.63-0.96 at 7 days). There was no significant difference in case of MACE at 30 days (RR 1.02; 95%CI 0.93-1.11). Heterogeneity was observed across the trials that reported major bleeding (χ2=14.71, 5 df, p=0.01, I2=66%) at 30 days, but not at 7 days for reported major bleeding, and also for net clinical outcomes and MACE both at 7 days and 30 days. Conclusion: This analysis further supports that Bivalirudin provides significantimprovement in net clinical outcomes and MACE with a significant reduction of bleedingcomplications.

Keywords


Major bleeding, Net clinical outcomes, MACE, Bivalirudin, Heparin

Full Text:

PDF

References


Stone GW, White HD, Ohman EM. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous

coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage

strategy (ACUITY) trial. Lancet 2007;369:907-919.

Stone GW, Witzenbichler B, Guagliumi G. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J

Med 2008;358:2218-2230

Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Büttner HJ, et al. Bivalirudin versus Unfractionated Heparin

during Percutaneous Coronary Intervention. N Engl J Med 2008;359:688-96.

Published 30 March 2016

DOI: 10.1234.67/jmpr.1014

JMPR 2016, 2, 21-26

Lincoff AM, Bittl JA, Kleiman NS. Comparison of Bivalirudin versus Heparin during percutaneous coronary intervention

(the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).

Am J Cardiol 2004;93:1092-1096.

Lincoff AM, Bittl JA, Harrington RA. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with

Heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized

trial. JAMA 2003;289:853-63.

Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus Heparin during coronary angioplasty for

unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study (BAT). Am Heart J

;142:952-959

Lincoff AM, Kleiman NS, Kottke-Marchant K. Bivalirudin with planned or provisional abciximab versus low-dose

Heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab

Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002;143:847-853

Bertrand ME, Simoons ML, Fox KA. Management of acute coronary syndromes in patients presenting without persistent

ST-segment elevation. Eur Heart J 2002;23:1809-40.

Xavier D, Pais P, Devereaux P. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective

analysis of registry data The Lancet 2008;371:1435-1442.

Gruentzig AR. Percutaneous transluminal coronary angioplasty. SeminRoentgenol 1981;16:152–153.

Graves EJ, Kozak LJ. Detailed diagnosis and procedures, National Hospital Discharge Survey, 1996. No. 138. Hyattsville,

MD: National Center for Health Statistics, 1998. (DHHS publication no. 98-1799.)

Braunwald E, Antman EM, Beasley JW. Management of patients with unstable angina and non-ST segment elevation

myocardial infarction: a report of the American College of Cardiology/American Heart Association Task

Force on Practice Guidelines [Serial on the Internet]. [cited 2009 May 15]. Available from:

http://www.acc.org/qualityandscience/clinical/guidelines/unstable/unstable_pkt.pdf

Braunwald E, Antman EM, Beasley JW. ACC/AHA guideline update for the management of patients with unstable

angina and non-ST-segment elevation myocardial infarction — 2002: summary article: a report of the American

College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management

of Patients With Unstable Angina). Circulation 2002;106:1893-900.

Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by Heparin-antithrombin

III but is susceptible to inactivation by antithrombin III independent inhibitors. J Clin Invest

;86:385-391.

Eitzman DT, Chi L, Saggin L, Schwartz RS, Lucchesi BR, Fay WP. Heparin neutralization by plateletrich thrombi:

role of platelet factor 4. Circulation 1994;89:1523-1529.

Xiao Z, Theroux P. Platelet activation with unfractionated Heparin at therapeutic concentrations and comparisons

with a low-molecular-weight Heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-256.

Sobel M, Fish WR, Toma N. Heparin modulates integrin function in human platelets. J VascSurg 2001;33:587-594.

Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa blockade in coronary artery disease. J Am CollCardiol

;35:1103-1115.

Kong DF, Topol EJ, Bittl JA. Clinical outcomes of Bivalirudin for ischemic heart disease. Circulation 1999;100;2049-

Stewart LA, Clarke MJ. Practical methodology of metaanalyses (overviews) using updated individual patient data.

Stat Med 1995;14:2057-2079.

Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial

Ischemia (TIMI) 7 trial. Circulation 1995;92:727-733.

Théroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized double-blind comparison of

two doses of Hirulog with Heparin as adjunctive therapy to streptokinase to promote early patency of the infarctrelated

artery in acute myocardial infarction. Circulation 1995;91:2132-2139.

White HD, Aylward PE, Frey MJ. Randomized, double-blind comparison of hirulog versus Heparin in patients

receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion

(HERO) Trial Investigators. Circulation 1997;96:2155-2161.

Bittl JA, Strony J, Brinker JA. Treatment with Bivalirudin (Hirulog) as compared with Heparin during coronary

angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med

;333:764-769.

Singh S, Molnar J, Arora R. Efficacy and Safety of BivalirudinVersus Heparins in Reduction of Cardiac Outcomes

in Acute Coronary Syndrome and Percutaneous Coronary Interventions. J CardiovascPharmacolTher2007; 12; 283-


Refbacks

  • There are currently no refbacks.